Yes, jitteriness is a recognized side effect of buspirone (Buspar).
Jitteriness occurs as a documented adverse effect of buspirone, appearing in controlled clinical trials and FDA labeling, though it affects only a small percentage of patients. 1
Evidence from FDA Drug Labeling
The FDA-approved prescribing information for Buspar explicitly lists nervousness (5% vs 1% placebo) and excitement (2% vs <1% placebo) as treatment-emergent adverse events occurring more frequently than placebo in controlled trials 1. While "jitteriness" itself is not listed as a separate category in the primary adverse events table, the FDA label does note that "headache, and jitteriness" were among the seven side effects occurring more often on stimulant than placebo in the context of discussing side effect profiles 2.
Additionally, the FDA label describes a "syndrome of restlessness, appearing shortly after initiation of treatment" that has been reported in some patients, which may represent akathisia or dopaminergic effects 1. This restlessness syndrome aligns clinically with what patients and providers describe as "jitteriness."
Clinical Research Evidence
Research specifically documenting buspirone-induced jitteriness includes:
A 1988 case series reported four patients (three with panic disorder, one with generalized anxiety disorder) who developed increased anxiety, agitation, restlessness, pressured speech, and racing thoughts on buspirone 3. These symptoms completely resolved after discontinuation, suggesting the jitteriness may result from unusual adrenergic sensitivity in susceptible patients.
A 1986 review of 984 patients found nervousness occurred in 4% of buspirone-treated patients versus 1% on placebo, and excitation in 2% versus <1% 4. These activating symptoms represent the clinical manifestation of jitteriness.
Clinical Context and Risk Factors
Patients with panic disorder may be at higher risk for buspirone-induced jitteriness 3. The mechanism likely involves buspirone's complex pharmacology—while primarily a 5-HT1A partial agonist, it also affects dopaminergic neurotransmission and may increase central noradrenergic activity 1, 5.
Management Approach
When jitteriness occurs with buspirone:
- Reduce the dose or slow titration - The FDA label recommends starting at 5 mg twice daily and titrating gradually 6
- Consider discontinuation if symptoms are distressing - Jitteriness typically resolves completely upon stopping the medication 3
- Avoid buspirone in patients with panic disorder who may be more sensitive to activating effects 3
Important Caveat
The overall incidence of jitteriness/nervousness with buspirone (4-5%) is substantially lower than the sedation seen with benzodiazepines (26-58%) 4, making buspirone's side effect profile generally more favorable for patients who can tolerate the occasional activating effects. However, for the subset of patients who experience jitteriness, it can be significant enough to warrant discontinuation.